The new EU compass could support small companies to grow their market share across Europe, assisted by fewer regulatory ...

Lilly licenses sintilimab from Suzhou-based biotech Innovent Biologics ... and Dr Jill Biden. Eli Lilly has unveiled a $2.5 billion deal to acquire rights to a breast cancer therapy being ...

SAN FRANCISCO and SUZHOU, China, Jan. 16 ... Innovent partners with over 30 global healthcare companies, including Eli Lilly, Sanofi, Incyte, Adimab, LG Chem and MD Anderson Cancer Center.

as it tries to carve out a share of a market currently dominated by Novo Nordisk and Eli Lilly. Mazdutide – a once-weekly injectable Innovent licensed from Lilly – was submitted to China's ...

SAN FRANCISCO and SUZHOU, China, Jan. 16, 2025 /PRNewswire/ -- Innovent ... Innovent partners with over 30 global healthcare companies, including Eli Lilly, Sanofi, Incyte, Adimab, LG Chem and MD ...

SY-009 is a novel SGLT1 inhibitor, that is not listed at home or abroad. With the permission of Eli Lilly Company, Suzhou Yabao Pharmaceutical Research and Development Co., Ltd., initiated the ...

Eli Lilly investors and analysts said they want to hear details from the company on how exactly it plans to grow U.S. sales ...

Eli Lilly is set to report fourth-quarter earnings early Thursday, with analysts expecting rising sales and profit in the first full quarter with the company's weight-loss drugs no longer in shortage.

Eli Lilly and Company (NYSE:LLY), a leading pharmaceutical giant with a market capitalization of $732 billion, has been ...